Clinical trials: Oral Squamous Cell Carcinoma (OSCC)
Oral Cancer, Lymph Node Metastasis
Neck Observation or Elective Neck Dissection in cT1N0M0 OSCC
To evaluate the clinical outcomes of 2-year lymph node metastasis rate, disease-free survival, overall survival, and health-related quality of life in the patients with cT1N0M0 oral squamous cell carcinoma, who receive primary…
- Trial name
- NCT06623266
- Testing
- Neck management
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Huashan Hospital
Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC)
A Bidirectional Observational Clinical Study of NAIC in the Treatment of Tumor Regression Patterns in LA-OSCC and LA-OPSCC
A prospective collection of 35 cases was conducted at Zhujiang Hospital of Southern Medical University. Patients diagnosed with locally advanced oral squamous cell carcinoma (LA-OSCC) or locally advanced oropharyngeal squamous…
- Trial name
- NCT07133958
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhujiang Hospital
Oral Squamous Cell Carcinoma (OSCC)
Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab
Chart review of records of patients treated for betel nut-induced oral cancer with pembrolizumab and cetuximab.
- Trial name
- NCT07015333
- Testing
- pembrolizumab and cetuximab
- Where
- Northern Mariana Islands
- Volunteers
- 31 people
- Sponsor
- Commonwealth Healthcare Corporation
Oral Squamous Cell Carcinoma (OSCC), Diagnosis
Trop2-targeting NIR-II Molecular Probe for Precision Diagnosis of Oral Cancer
Given the morphological and clinical similarities between certain oral malignant neoplasms and benign conditions such as oral ulcerations or inflammatory lesions, the potential for misdiagnosis is significant.
- Trial name
- NCT07794813
- Testing
- TTP-ICG incubation solution
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Yunnan Cancer Hospital
Oral Squamous Cell Carcinoma, Neoadjuvant Chemotherapy
Melatonin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma
Backgrounds Squamous cell carcinoma of the oral cancer (OSCC) is the sixth most common malignancy. Surgery is the mainstay of treatment for oral cancers.
- Trial name
- NCT04137627
- Testing
- Melatonin 20 MG Oral Capsule
- Where
- Indonesia
- Volunteers
- 50 people
- Sponsor
- Universitas Indonesia
Oral Squamous Cell Carcinomas
Tobacco, Alcohol and Cancerization of the Oral Mucosa (TACO)
The goal of this project is to describe somatic mutations of healthy oral mucosa from patients with oral squamous cell carcinoma (OSCC).
- Trial name
- TACO (NCT06425146)
- Testing
- Cytobrush sample, Blood sampling
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Leon Berard
Tongue Neoplasms, Carcinoma
Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line
In vitro study to examine whether luteolin and nano-luteolin exert an inhibitory effect on tongue squamous cell carcinoma cell line by inducing apoptosis, and to assess if nano-luteolin has more efficient apoptotic activity than…
- Trial name
- NCT03288298
- Testing
- luteolin, nano-luteolin
- Volunteers
- 4 people
- Sponsor
- Cairo University
Oral Cancer, Osteosarcoma
Quantitative Margin Assessment Using High-resolution Positron Emission Tomography - Computed Tomograhy
The primary endpoint is the assessment of the clinical value of a novel high-resolution mobile PET-CT scanner for intraoperative margin assessment in oral squamous cell carcinoma, soft tissue sarcoma and osteosarcoma surgery.
- Conditions
- Oral Cancer, Osteosarcoma, Soft Tissue Sarcoma, Oral Squamous Cell Carcinoma (OSCC)
- Trial name
- qMAP (NCT06726512)
- Testing
- XEOS AURA 10
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- University Medical Center Groningen
Oral Squamous Cell Carcinoma
Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine Learning
Application Management Team: PI - Siu Wai Choi; email - htswchoi@hku.hk Delegates - Chui Shan Chu; email: sunshine.c@connect.hku.hk FollowUpUsers - Chui Shan Chu; email:sunshine.c@connect.hku.hk
- Trial name
- NCT04543266
- Testing
- Surgery
- Where
- Hong Kong
- Volunteers
- 500 people
- Sponsor
- The University of Hong Kong
Oral Cavity Squamous Cell Carcinoma
Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)
This is a study of oral nisin administration in patients with OSCC who are undergoing complete surgical resection surgery with or without adjuvant radiation/chemoradiation as part of their routine care at the University of…
- Trial name
- NCT06097468
- Testing
- NisinZ® P, Surgery (non-interventional, standard of care)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Francisco
Oral Squamous Cell Carcinoma
Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma
The research and development of novel anti-tumor agents in oral cancer is slow, the investigation of repositioning use of currently available drugs in clinical, such as a selective cyclooxygenase-2 (COX-2) inhibitor…
- Trial name
- NCT02739204
- Testing
- Celecoxib
- Where
- Taiwan
- Volunteers
- 270 people
- Sponsor
- China Medical University Hospital
Head and Neck Cancer
Iparomlimab and Tuvonralimab With With Cetuximab in Resectable OSCC
This is a single-center, single-arm phase II clinical study designed to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab combined with cetuximab in patients with locally advanced resectable oral squamous cell…
- Trial name
- NCT07882888
- Testing
- iparomlimab and tuvonralimab combined with cetuximab
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Oral Squamous Cell Carcinoma (OSCC)
Determination of ALDH1b1 and ALDH2 Polymorphisms Frequency in the Brazilian Population
A case-control study with oral squamous cell carcinoma (OSCC) patients from Instituto do Câncer do Estado de São Paulo (ICESP) and healthy volunteers.
- Trial name
- ALDH2020 (NCT04270201)
- Testing
- Saliva collection
- Where
- Brazil
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma
Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
The purpose of this study is to evaluate the effectiveness and safety of the combination therapy of immunotherapy (Sintilimab) with targeted therapy (Cetuximab) as a possible treatment before and after surgery for locally…
- Conditions
- Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma, Resectable Oral and Oropharyngeal Squamous Cell Carcinoma
- Trial name
- OSCC (NCT07079410)
- Testing
- Sintilimab+Cetuximab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Zhongshan Hospital
Head and Neck Cancer
Biomarkers in Tissue Samples From Patients Who Have Undergone Neck Dissection for Oral Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899704
- Testing
- microarray analysis, allele-specific oligonucleotide real-time quantitative polymerase chain reaction, diagnostic laboratory biomarker analysis
- Where
- United States
- Sponsor
- Alliance for Clinical Trials in Oncology
HNSCC, OSCC
Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma
To investigate the neoadjuvant chemoimmunotherapy regimen of Ivonescimab combined with chemotherapy (Paclitaxel plus Cisplatin/Carboplatin) for the treatment of locally advanced resectable oral squamous cell carcinoma and…
- Conditions
- HNSCC, OSCC, OPSCC, Ivonescimab
- Trial name
- NCT07686575
- Testing
- Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Zhujiang Hospital
Oral Squamous Cell Carcinoma, Neoadjvant Therapy
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
To evaluate the efficacy of neoadjuvant anti-PD-1 plus anti-VEGFR therapy for patients with locally advanced and resectable oral squamous cell carcinoma, and the CPS>10 in the biopsy samples.
- Conditions
- Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1, Anti-VEGFR
- Trial name
- NCT05069857
- Testing
- Camrelizumab (anti-PD-1 inhibitor), Apatinib (anti-VEGFR inhibitor)
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Mouth Neoplasms, Carcinoma, Squamous Cell
Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage
The purpose of this study is to To confirm the predictive value of CCND1 for TPF induction in cN2 patients with OSCC
- Trial name
- NCT02290145
- Testing
- TPF group, surgery group, Post-operative radiotherapy
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC)
Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma
The purpose of this study is to evaluate the effectiveness and safety of the combination therapy of immunotherapy (Tislelizumab), targeted therapy (Cetuximab), with chemotherapy (Cisplatin and Nab-paclitaxel) as a possible…
- Conditions
- Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC), Resectable Oral and Oropharyngeal Squamous Cell Carcinoma, Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma
- Trial name
- OSCC (NCT06728618)
- Testing
- Drug: Tislelizumab, Cetuximab, Cisplatin and Nab-paclitaxel
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Zhongshan Hospital
Neoplasm
Modern Hybrid Imaging in Patients With OSCC
Prospective diagnostic study to determine the diagnostic accuracy of preoperative 18F--fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in detecting local tumor extent, cervical lymph node…
- Trial name
- PETOSCC (NCT04280159)
- Where
- Germany
- Volunteers
- 265 people
- Sponsor
- Wuerzburg University Hospital